Pacira Pharma (PCRX) Misses Q4 EPS by 34c, provides guidance

Pacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.54, $0.34 worse than the analyst estimate of $0.88. Revenue for the quarter came in at $181.2 million versus the consensus estimate of $180.85 million.

GUIDANCE:

Pacira Pharma sees FY2024 revenue of $680-705 million, versus the consensus of $716.6 million.
Non-GAAP gross margin of 74% to 76%;
Non-GAAP R&D expense of $70 million to $80 million;
Non-GAAP SG&A expense of $245 million to $265 million; and
Stock-based compensation of $50 million to $55 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
• Dutch Bros Inc. (BROS) PT Raised to $90 at DA Davidson on Sales/Earnings Upside